Takeda Pharmaceutical Co (0RN3) Share Price & Analysis
0RN3 Stock Chart & Stats
- Day’s Range
- EUR 35.20 - EUR 35.20
- 52-Week Range
- EUR 35.20 - EUR 35.20
- Previous Close
- EUR 35.20
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 60.13B
- Enterprise Value
- EUR 13.51T
- Total Cash (Recent Filing)
- EUR 454.40B
- Total Debt (Recent Filing)
- EUR 4.58T
- Price to Earnings (P/E)
- 27.2
- Beta
- N/A
- Next Earnings
- Jan 28, 2027 (Est.)
- EPS Estimate
- 0.5
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.45%
Bulls Say, Bears Say
Bulls Say
Profitability And Cash Generation
Strong gross and EBITDA margins show that Takeda’s branded and specialty-biopharma portfolio generates meaningful operating profit. Positive operating and free cash flow provide internal funding for research, launches, debt service, and shareholder returns over the coming quarters.
New Product And Pipeline Growth
Rapid growth from recently launched products gives Takeda a path to offset mature-brand erosion and diversify future revenue. ORZEYFUL, MIMRYLO, and zasocitinib can broaden the commercial base as launches, regulatory progress, and physician adoption develop.
Transformation Savings
The savings program is already producing measurable procurement benefits and can improve operating leverage beyond the near term. Releasing funds from the cost base should help Takeda finance new launches and R&D while supporting profitability despite portfolio transitions.
Bears Say
Mature Portfolio Erosion
Loss of exclusivity and weakness in mature products create a continuing revenue headwind that newer medicines must replace. This raises execution pressure on launches and pipeline conversion, and can keep growth modest while the portfolio mix shifts.
Recent Cash-flow Pressure
Takeda remains cash generative, but the recent deterioration in free cash flow indicates weaker conversion than in prior periods. If sustained, lower cash generation could constrain investment flexibility, debt reduction, and the ability to absorb launch or restructuring costs.
Zasocitinib Dose Uncertainty
The lack of a consistent dose response introduces uncertainty around zasocitinib’s ulcerative-colitis development path and potential commercial scope. Additional evaluation may delay Phase III decisions, increase development complexity, and reduce confidence in this pipeline opportunity.
Takeda Pharmaceutical Co News
0RN3 FAQ
What was Takeda Pharmaceutical Co’s price range in the past 12 months?
What is Takeda Pharmaceutical Co’s market cap?
When is Takeda Pharmaceutical Co’s upcoming earnings report date?
How were Takeda Pharmaceutical Co’s earnings last quarter?
Is Takeda Pharmaceutical Co overvalued?
Does Takeda Pharmaceutical Co pay dividends?
What is Takeda Pharmaceutical Co’s EPS estimate?
How many shares outstanding does Takeda Pharmaceutical Co have?
What happened to Takeda Pharmaceutical Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Takeda Pharmaceutical Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Julie So-Young Kim
- Employees
- 47,029
- Website
- www.takeda.com
- Address
- 1-1, Nihonbashi-Honcho 2-chome, Tokyo, OS, 103-8668, JP
Takeda Pharmaceutical Co (0RN3) Earnings & Revenues
0RN3 Company Deck
0RN3 Earnings Call
Earnings Call SentimentPositive
The call was broadly optimistic, with strong progress in launches, regulatory milestones, late-stage pipeline data, ENTYVIO performance and transformation savings. These positives were partly offset by the 1% constant-exchange-rate revenue decline, core EPS pressure, mature-portfolio headwinds, weaker intravenous immunoglobulin and albumin performance, and uncertainty around zasocitinib's ulcerative-colitis dose response. Highlights significantly outweighed the stated challenges.
View all GB:0RN3 earnings summaries0RN3 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 2 |
| Technical Analysis | 1 | 1 | 0 |
| Moving Averages | 6 | 4 | 2 |